Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz® a Biosimilar to Simponi® (golimumab)

REYKJAVIK, ICELAND and LONDON, UK (November 20, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Commission (EC) has granted marketing authorizations in the European Economic Area (EEA) for Gobivaz®, Alvotech’s biosimilar to Simponi® (golimumab). The authorizations cover Gobivaz® 50 mg/0.5 mL and 100mg/mL in both pre-filled syringe with passive needle safety guard and autoinjector formats, for the treatment of adults with rheumatoid arthritis in combination with methotrexate, psoriatic arthritis with or without methotrexate, axial spondyloarthritis, ulcerative colitis and for the treatment of juvenile idiopathic arthritis in children 2 years of age and older in combination with methotrexate. The approvals apply across the European Economic Area. The EC approval follows the positive opinion issued in September by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). “This milestone marks the second biosimilar to receive approval through our partnership with Advanz Pharma and further strengthens our presence in Europe. As the first biosimilar to Simponi® (golimumab) to gain approval in the European market, we are committed to ensuring dependable access to high quality biologic medicines for people living with immune-mediated diseases. We remain focused on delivering consistent supply and providing value to healthcare systems throughout the region” said Robert Wessman, Chairman and Chief Executive Officer of Alvotech. “We welcome the EC approval of Gobivaz®, an important milestone in our partnership with Alvotech. Expanding access to high-quality biosimilars is central to Advanz Pharma’s mission, and this approval enables us to offer patients across Europe a valuable new treatment option for immune-mediated diseases.” said Steffen Wagner, Chief Executive Officer, Advanz Pharma. Under the partnership between Alvotech and Advanz Pharma, Alvotech is responsible for the development and commercial supply of Gobivaz®, while Advanz Pharma holds the registration and exclusive commercialization rights in the EEA and the UK. The EC approval of Gobivaz® was based on a totality of evidence, including analytical and clinical data. In April 2024, Alvotech announced positive top-line results from a confirmatory clinical study comparing efficacy, safety, and immunogenicity between its biosimilar candidate AVT05 and the reference product Simponi® in patients with moderate to severe rheumatoid arthritis (clintrials.gov/study/NCT05842213). In November 2023, Alvotech announced positive topline results from a pharmacokinetic study which assessed the pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® in healthy adult participants (clintrials.gov/study/NCT05632211). About AVT05 AVT05 (golimumab) has been approved as Golimumab BS (golimumab) in Japan and as Gobivaz (golimumab) in the European Economic Area. Dossiers are under review in multiple countries globally. Golimumab is a monoclonal antibody that inhibits tumor necrosis factor alpha (TNF alpha). Elevated TNF alpha levels have been implicated in several chronic inflammatory diseases such as rheumatoid arthritis [1]. Sources [1] Simponi product information Use of Trademarks Simponi® is a registered trademark of Johnson & Johnson. Gobivaz® is a trademark of Advanz Pharma. About Alvotech Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline includes eight disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release. About Advanz Pharma Partner of choice in specialty, hospital, and rare disease medicines. Advanz Pharma is a global pharmaceutical company with the purpose to improve patients’ lives by providing and enhancing the specialty, hospital, and rare disease medicines they depend on. Our headquarters are in London, UK. We have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia, a Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialization partner network. Advanz Pharma’s product portfolio and pipeline comprises innovative medicines, biosimilars & specialty generics, and originator brands. Our products cover a broad range of therapeutic areas, including hepatology, rheumatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and, more broadly, rare disease medicines. Our ambition is to be a partner of choice for the commercialization of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. In line with our ambition, we are partnering with biopharma and development companies to bring medicines to patients. We can only achieve this due to our dedicated and highly qualified employees, acting in line with our company values of entrepreneurship, speed, and integrity. Alvotech Forward Looking Statements[REPLACE WITH SHORTER VERSION] Advanz Pharma Forward Looking StatementsCertain statements in this press release are forward-looking statements. These statements may be identified by words such as “anticipate”, "expectation", "belief', "estimate", "plan", "target”, “project”, “will”, “may”, “should” or "forecast" and similar expressions, or by their context. Although Advanz Pharma believes that these assumptions were reasonable when made, by their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions affecting the industry, intense competition in the markets in which Advanz Pharma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Advanz Pharma’s markets, and other factors beyond the control of Advanz Pharma. Neither Advanz Pharma nor any of its directors, officers, employees, advisors, or any other person is under any obligation to update or keep current the information contained in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this press release. Statements contained in this press release regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. No obligation is assumed to update any forward-looking statements. The information contained in this press release is provided as at the date of this document and is subject to change without notice. MEDIA CONTACTSAlvotech Global Communications and Investor RelationsBenedikt [email protected] Advanz Pharma Global Corporate CommunicationsCourtney [email protected] Related Articles Press Releases — Patent Settlement Secures Pathway for ADVANZ PHARMA and Alvotech to Market Eylea® Biosimilar 30 Jan 2026 Learn more Press Releases — ADVANZ PHARMA Acquires Territory Rights to Progynova® and Cyclo-Progynova® in Selected Countries in EMEA and Global Rights to Ilomedin® 18 Dec 2025 Learn more Press Releases — Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz® a Biosimilar to Simponi® (golimumab) 20 Nov 2025 Learn more Press Releases — Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA 06 Nov 2025 Learn more × You are leaving the ADVANZ PHARMA site If you agree, then please click "YES" to proceed. If you do not wish to be linked to this website, please click "NO" to dismiss this message. YES NO About News Partner of Choice Contact Ethics & Transparency Modern Slavery Statement Product Risk Materials ADVANZ PHARMA for Patients Terms & Conditions Privacy Policy Recruitment Scams Recruitment Privacy Notice Follow us on LinkedIn This is our global website, intended for visitors seeking information on ADVANZ PHARMA's worldwide business. Copyright 2026 ADVANZ PHARMA®. All Rights Reserved × Formal Sale Process INFORMATION REGARDING FORMAL SALE PROCESS ACCESS TO THIS AREA OF THE WEBSITE MAY BE RESTRICTED UNDER SECURITIES LAWS IN CERTAIN JURISDICTIONS. THIS NOTICE REQUIRES YOU TO CONFIRM CERTAIN MATTERS (INCLUDING THAT YOU ARE NOT RESIDENT IN SUCH A JURISDICTION), BEFORE YOU MAY OBTAIN ACCESS TO THE INFORMATION IN THIS AREA OF THE WEBSITE. THESE MATERIALS ARE NOT DIRECTED AT OR TO BE ACCESSED BY PERSONS RESIDENT IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION OR WOULD RESULT IN A REQUIREMENT TO COMPLY WITH ANY CONSENT OR OTHER FORMALITY WHICH ADVANZ PHARMA CORP. LIMITED REGARDS AS UNDULY ONEROUS. You are attempting to enter the area of this website that is designated for the publication of documents and information in connection with ADVANZ PHARMA Corp. Limited (“ADVANZ”) formal sale process. The information contained in this area of this website is being made available in good faith and for information purposes only in compliance with the City Code on Takeovers and Mergers and is subject to the terms and conditions set out below. In particular, the information contained in this area of this website does not constitute an offer to sell or otherwise dispose of or any invitation or solicitation of any offer to purchase or subscribe for any securities in any jurisdiction in which such offer or solicitation is unlawful. Access to the Website If you would like to view this area of the website, please read this notice carefully. This notice applies to all persons who view this area of the website and, depending on where you are located, may affect your rights or responsibilities. ADVANZ reserves the right to amend or update this notice at any time and you should, therefore, read it in full each time you visit this area of the website. In addition, the contents of this area of the website may be amended at any time in whole or in part at the sole discretion of ADVANZ. Overseas Persons As a consequence of legal restrictions, the release, publication or distribution of information contained in this area of the website in certain jurisdictions or to certain persons may be restricted or unlawful. All persons resident or located outside the United Kingdom who wish to view this area of the website must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so and should inform themselves of, and observe, any applicable legal or regulatory requirements applicable in their jurisdiction. If you are resident or located in a country that renders the accessing of this area of the website or parts thereof illegal, whether or not subject to making certain notifications or taking other action, you should not view this area of the website. It is your responsibility to satisfy yourself as to the full observance of any relevant laws and regulatory requirements. If you are in any doubt, you should not continue to seek to access this area of the website. You should not forward, transmit or show the announcements, information or documents contained in this area of the website to any person. In particular, you should not forward or transmit the announcements, information or documents contained in this area of the website to any jurisdiction where it would be unlawful to do so. Forward Looking Statements This area of the website contains “forward-looking statements”. These statements are based on the current expectations of the management of ADVANZ and are naturally subject to uncertainty and changes in circumstances. Forward-looking statements include, without limitation, statements typically containing words such as “intend”, “expect”, “anticipate”, “target”, “estimate”, “plan”, “strategy”, “will”, “should”, “may”, “goal”, “seek”, “believe”, “predict”, “continue”, “future”, “could”, “can” and words of similar import. These forward looking statements are not guarantees of future performance. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by such forward-looking statements. These factors include, but are not limited to, changes in economic conditions, changes in the level of capital investment, success of business and operating initiatives and restructuring objectives, costs associated with research and development, changes in the prospects for products in the research and development pipeline of ADVANZ, customers’ strategies and stability, changes in the regulatory environment, fluctuations of interest and exchange rates, the outcome of litigation, government actions and natural phenomena such as floods, earthquakes and hurricanes. Other unknown or unpredictable factors could cause actual results to differ materially from those in the forward-looking statements. ADVANZ does not undertake any obligation to update publicly or revise forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent legally required. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. Neither ADVANZ nor any of its affiliated companies undertakes any obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent legally required. Responsibility In relation to any document, announcement or information contained in this area of the website, the only responsibility accepted by the directors of ADVANZ (the “Responsible Persons”) is for the correctness and fairness of its reproduction or presentation, unless the responsibility statement in any relevant document expressly provides otherwise. None of the Responsible Persons, ADVANZ or its affiliated companies have reviewed and none of them is responsible for, or accepts any liability in respect of, any information on any other website that may be linked to this website by a third party. The documents included in this area of the website speak only at the specified date of the relevant document and neither ADVANZ nor any of its affiliated companies has or accepts any responsibility or duty to update such documents (other than to the extent such duty arises as a matter of law). If you are in any doubt about the contents of this area of the website or the action you should take, you should seek your own financial advice from an independent financial adviser authorised under the Financial Services and Markets Act 2000 or, if you are located outside the United Kingdom, from an appropriately authorised independent financial adviser. THE DOCUMENTS IN THIS AREA OF THE WEBSITE MAY NOT BE DOWNLOADED, FORWARDED, TRANSMITTED OR SHARED WITH ANY OTHER PERSON EITHER IN WHOLE OR IN PART WHERE TO DO SO WOULD OR MAY CONSTITUTE A BREACH OF ANY APPLICABLE LOCAL LAWS OR REGULATIONS. Electronic versions of these materials are not directed at or accessible by persons resident in any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction. This notice shall be governed by, and interpreted in accordance with, English law. Confirmation of Understanding and Acceptance of Disclaimer. If you do not click “I AGREE” below you will not be permitted access to this area of the website. I certify that I am not (nor do I act on behalf of someone who is) resident in any country that renders the accessing of this area of the website or parts thereof illegal.I agree that I will not forward, transfer or distribute (by any means including by electronic transmission) any documents included in this area of the website either in whole or in part to any person in any jurisdiction where such distribution may be restricted by applicable law or regulation.I represent and warrant to ADVANZ that I intend to access this area of the website for information purposes only, that I have read and understood this notice and that I understand that it may affect my rights or responsibilities.I agree to be bound by the terms of this notice. I don't agree I agree let qmQuote = null; {"@context":"https://schema.org","@graph":[{"@type":"Organization","@id":"#organization","name":"ADVANZ PHARMA","url":"https://www.advanzpharma.com/"},{"@type":"WebSite","@id":"#website","name":"ADVANZ PHARMA","publisher":{"@id":"#organization"},"url":"https://www.advanzpharma.com/"},{"@type":"WebPage","@id":"#page","author":{"@id":"#organization"},"isPartOf":{"@id":"#website"},"url":"https://www.advanzpharma.com/news/2025/alvotech-and-advanz-pharma-receive-marketing-approval-across-the-european-economic-area-for-gobivaz-a-biosimilar-to-simponi-golimumab","name":"Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz® a Biosimilar to Simponi® (golimumab)","description":"Partner of choice in specialty, hospital, and rare disease medicines."}]}

The release as fetched from its publisher. advanzpharma.com ↗